Navigation Links
Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Amgen (NASDAQ: AMGN) today announced the results of the "145 study", a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of Aranesp(R) (darbepoetin alfa) in 600 previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving platinum-containing chemotherapy. The study demonstrated no statistically significant difference in risk of death (overall survival Aranesp compared to placebo Hazard Ratio (HR): 0.93, 95% CI: 0.78 to 1.11) or investigator determined progression-free survival (HR: 1.02, 95% CI: 0.86 to 1.21).

The study demonstrated a significant change in hemoglobin concentration from baseline in favor of Aranesp (a co-primary endpoint). Aranesp-treated patients also experienced a significantly lower risk of blood transfusions (HR: 0.40, 95% CI: 0.29 to 0.55). The overall safety profile, including thromboembolic events, was consistent with that described in the U.S. label.

"The 145 study is a component of Amgen's ongoing pharmacovigilance program designed to evaluate the effect of Aranesp on long-term survival in patients with chemotherapy-induced anemia. This study had higher initiation and maintenance hemoglobin targets (Hb less than or equal to 13 g/dl) than in the U.S. label," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "These results contribute to the growing body of evidence on ESA safety, reinforcing the neutral impact of ESAs on survival in cancer patients suffering from chemotherapy-induced anemia."

Amgen initiated the SCLC study in 2002 after results from a previous Phase 3 study showed a trend towards improved survival in patients with lung cancer. The 145 study was designed to evaluate whether increasing or maintaining hemoglobin concentrations with Aranesp, when administered with platinum-containing chemotherapy in patien
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: ... on significant strategic and financial initiatives at its ... Conference is hosted by Peter H. Soderberg, president ... on the following topics: ,, Status of ... development and financial updates Smart technologies that ...
(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...
(Date:12/15/2009)... SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... AMLN ), Eli Lilly and Company (NYSE: ... ALKS ) today announced positive results from ... investigational diabetes therapy, to BYETTA® (exenatide) injection taken ... After 24 weeks of treatment, patients taking exenatide ...
Breaking Medicine Technology:Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 1First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 2First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 3First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 4Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 1Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 2Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 3Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 1Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 2
... /PRNewswire/ -- At the April AACR,Annual Meeting, Indivumed ... a new drug test-platform to predict drug,response in ... currently the first,choice for cancer drug testing. During ... protein expression patterns,change significantly, thereby losing many of ...
... 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive results ... drug, IPLEX(TM), in,patients with myotonic muscular dystrophy (DM1)., ... at,the University of Rochester School of Medicine and ... of IPLEX up to 1,mg/kg/day in six patients ...
Other Medicine Technology:Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4
(Date:12/15/2009)... require that certain businesses with large areas where people gather, ... available. Fire and rescue personnel agree that for any size ... , ... Issaquah, WA (PRWEB) December ... that certain businesses with large areas where people gather, need ...
(Date:12/15/2009)... SAN DIEGO, Dec. 15 "The entire San ... mourns the passing of Sol Price on December 14, ... standards of integrity, loyalty and ethics in his business, ... and thoughtful humanitarian who truly understood the responsibility of ... and his legacy will live on through his countless ...
(Date:12/15/2009)... UT Southwestern Medical Center researchers have provided ... unique observable characteristics seen in patients with an ... reported online and in the December issue of ... suggest that patients with atypical progeroid syndrome ... diagnosed with two similar but more well-defined accelerated ...
(Date:12/14/2009)... and synthetic red-blood-cell-like particles carry oxygen, drugs, and more… ... ... Scientists at UC Santa Barbara, in collaboration with scientists at ... the characteristics and key functions of natural red blood cells, ... , , , , ,The primary function of natural red ...
(Date:12/14/2009)... Fla., Dec. 14 Abbott (NYSE: ... definitive agreement to acquire STARLIMS Technologies Ltd. ... of laboratory information management systems, for approximately ... acquisition strengthens Abbott,s competitive position in the ... to help laboratories efficiently store, retrieve and ...
Breaking Medicine News(10 mins):Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4
... "TOGETHER ... HIV STOPS WITH US",is the ... in areas across,the country including: Boston, Long Beach ... real HIV positive people, and a,wide spectrum of ... members,friends, care providers and partners talking about real ...
... often, it reduces bleeding problems, study finds , , MONDAY, Aug. ... from the wrist rather than the groin reduces the incidence ... The approach, using the radial artery in the wrist, is ... analysis of almost 600,000 catheterizations in a national database, said ...
... LOS ANGELES, Aug. 18 Today a representative ... Term Care Workers, Local,6434 ("ULTCW") filed a letter ... ("UHW-W")., In the letter written to President ... -- an elected Vice President of ULTCW and,member ...
... PALO ALTO, Calif., Aug. 18 Based on ... & Sullivan presents ConforMIS,with the 2008 North American ... This recognition is in support of the company,s,unique ... each,individual unlike traditional implants that require surgeons to ...
... In up to 20 percent of people infected with ... and cross into the brain, resulting in HIV-associated dementia ... Einstein College of Medicine of Yeshiva University have found ... of intestinal bacteriaa chemical present in high levels in ...
... Market Intelligence and Competitive Analysis from, Thomson Reuters ... LONDON and PHILADELPHIA, Aug. 18 Thomson ... businesses and,professionals, has announced the availability of the ... Launched more than two years,ago, the quarterly Pharma ...
Other Medicine News:Health News:New HIV Prevention/Anti-Stigma Campaign Featuring HIV Positive & Negative Persons 'TOGETHER' Launches Across the Nation 2Health News:Reaching the Heart Through the Wrist 2Health News:Reaching the Heart Through the Wrist 3Health News:Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies 2Health News:Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies 3Health News:Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies 4Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 2Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 3Health News:Chemical liberated by leaky gut may allow HIV to infect the brain, Einstein scientists find 4Health News:The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 2Health News:The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 3
Enzyme Immunoassay of Protein C Antigenby ELISA Method, 96 tests...
Substrate Plasma for Factor II Assay by STA© Analyzers. Freeze-dried human serum and absorbed bovine plasma, the latter providing factor V and fibrinogen to the test system....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Medicine Products: